Receptos to Hold Fourth Quarter and Year End 2014 Financial Results Conference Call
26 Febbraio 2015 - 2:00PM
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company
developing therapeutic candidates for the treatment of immune and
metabolic diseases, will review financial results for the fourth
quarter and year ended December 31, 2014 on Tuesday, March 3 after
the markets close. The announcement will be followed by a live
webcast and conference call at 5:00 p.m. Eastern time (2:00 p.m.
Pacific time).
Receptos management will host the call and webcast to discuss
financial results and recent business highlights. The live
call may be accessed by phone by calling (866) 757-6808 (domestic)
or (760) 536-5211 (international), conference ID 90059109. The
webcast can be accessed live on the Investor Relations section of
the Receptos website at www.receptos.com and will be archived for
14 days following the call. A replay of the call will be
available by phone by calling (855) 859-2056 or (404) 537-3406,
conference ID 90059109.
About Receptos
Receptos is a biopharmaceutical company developing
therapeutic candidates for the treatment of immune and metabolic
diseases. The Company's lead program, RPC1063, is a sphingosine
1-phosphate 1 and 5 receptor small molecule modulator in
development for immune indications including RMS and
IBD. Patents supporting RPC1063 were exclusively licensed to
Receptos from The Scripps Research
Institute (TSRI). The Company is also developing RPC4046,
an anti-interleukin-13 (IL-13) antibody for eosinophilic
esophagitis (EoE), an allergic/immune-mediated orphan disease.
CONTACT: Media and Investor Contact:
Graham K. Cooper
Chief Financial Officer, Receptos
(858) 652-5708
gcooper@receptos.com
Grafico Azioni RECEPTOS, INC. (NASDAQ:RCPT)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni RECEPTOS, INC. (NASDAQ:RCPT)
Storico
Da Lug 2023 a Lug 2024
Notizie in Tempo Reale relative a (MM) (NASDAQ): 0 articoli recenti
Più Articoli Notizie